drugset / Trial / NCT07293260
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this trial is to evaluate the effect of olpasiran, compared to placebo, on non-calcified plaque (NCP) volume as measured by Coronary Computed Tomography Angiography (CCTA).
Timeline
- Start
- 2026-03-23
- Primary completion
- 2028-06-15
- Completion
- 2028-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olpasiran | Unknown | — | Subcutaneous |